TeamHow do semaglutide, tirzepatide, and retatrutide compare for weight loss?
Asked by PeptidePub Team · 5h ago
These three peptides are often discussed as if they were simply stronger versions of the same product. Buyers get a clearer comparison by looking at receptor targets, trial results, current price per mg, and the quality of vendor testing.
Related prices:Retatrutide price comparison →Tirzepatide price comparison →Semaglutide price comparison →
1 Answer
TeamPeptidePub Team · 5h ago
All three have produced substantial weight loss in large trials, but they target different receptor combinations and the headline percentages come from separate studies, not a head-to-head contest.\n\nSemaglutide activates GLP-1. In STEP 1, the 2.4 mg group lost about 14.9% of body weight on average at 68 weeks.\n\nTirzepatide activates GLP-1 and GIP. In SURMOUNT-1, the 15 mg group lost about 20.9% on average at 72 weeks.\n\nRetatrutide activates GLP-1, GIP, and glucagon receptors. In TRIUMPH-1, the 12 mg group lost 28.3% on average at 80 weeks, or about 70.3 pounds. About 45.3% reached at least 30% weight loss. Those are unusually strong results, but there is no direct retatrutide-versus-tirzepatide trial, and the studies differed in length, participants, and design.\n\nFor buyers, the practical comparison goes beyond the biggest percentage:\n\n1. Match the compound to the research goal and evidence lane.\n2. Compare total project cost, not just vial price. Convert each offer to effective price per mg after discounts and shipping.\n3. Require a recent, lot-matched COA from a named independent lab with identity, purity, and net-content evidence.\n4. Do not assume a retail vial is equivalent to clinical-trial material. Verify the exact compound, batch, and fill amount.\n5. Plan around tolerability data too. GI effects occur across this category, and retatrutide trials also reported dose-related dysesthesia.\n\nFor deeper retatrutide evidence, see https://www.peptidepub.com/peptides/retatrutide. Compare current offers at https://www.peptidepub.com/prices/semaglutide, https://www.peptidepub.com/prices/tirzepatide, and https://www.peptidepub.com/prices/retatrutide. Then use https://www.peptidepub.com/vendors to compare testing transparency before checkout.\n\nBottom line: semaglutide has the longest established GLP-1 lane, tirzepatide raises the average outcome with dual agonism, and retatrutide currently has the strongest separate-trial headline. Compare evidence, verified mg, and vendor proof together.
Your answer
Loading…
For research use only — no medical advice. Community rules